2-(2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)ethylamine | 40619-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)ethylamine
• 英文别名: 2-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-ethylamine；1-(2-Aminoethyl)-5,6-dihydro-4H-pyrrolo<3.2.1-i,j)chinolin；1,7-Trimethylenetryptamine；2-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)ethanamine
• CAS: 40619-71-4
• 化学式: C₁₃H₁₆N₂
• 分子量: 200.283
• InChiKey: SZZOKSZDRAYQNN-UHFFFAOYSA-N

物化性质

• 沸点：
  397.9±27.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  31
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)ethylamine 、 环丁基甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以46%的产率得到N-[2-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)ethyl]cyclobutanecarboxamide
  参考文献：
  名称：

  Design, synthesis and melatoninergic activity of new unsubstituted and β,β′-difunctionalised 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-alkanamides

  摘要：

  A series of new 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-alkanamides, with and without alkyl and cycloalkyl moieties in the P-position of the alkanamido side chain, have been prepared and tested for their ability to activate pigment granule aggregation in Xenopus laevis melanophores and bind to the recombinant human MT1 and MT2 melatonin receptor subtypes expressed in NIH 3T3 cells. An increase of the spacer's length in the side chain by a methylene unit (from 17d to 21d) leads to a six-fold decrease in antagonistic activity. On the other hand, the introduction of two methyl groups in the beta-position of the side chain of 17a induces agonist potency (compound 24), implying thus that the two beta-methyl groups are not only tolerated by the receptor, but constitute functional probes in its dynamic agonist-antagonist conformational equilibrium. The presence of more bulky beta-substituents, regardless of the size of the R group, compounds 24a,b, seems to lead to antagonism and to a noteworthy MT2 subtype selectivity. Last, the new N1-C7 annulated derivatives presented herein are substantially more potent than their respective N1-C2 annulated counterparts, previously reported. (c) 2007 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2007.01.005
• 作为产物：
  描述：

  (2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)acetamide 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 2-(2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)ethylamine
  参考文献：
  名称：

  Design, synthesis and melatoninergic activity of new unsubstituted and β,β′-difunctionalised 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-alkanamides

  摘要：

  A series of new 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-alkanamides, with and without alkyl and cycloalkyl moieties in the P-position of the alkanamido side chain, have been prepared and tested for their ability to activate pigment granule aggregation in Xenopus laevis melanophores and bind to the recombinant human MT1 and MT2 melatonin receptor subtypes expressed in NIH 3T3 cells. An increase of the spacer's length in the side chain by a methylene unit (from 17d to 21d) leads to a six-fold decrease in antagonistic activity. On the other hand, the introduction of two methyl groups in the beta-position of the side chain of 17a induces agonist potency (compound 24), implying thus that the two beta-methyl groups are not only tolerated by the receptor, but constitute functional probes in its dynamic agonist-antagonist conformational equilibrium. The presence of more bulky beta-substituents, regardless of the size of the R group, compounds 24a,b, seems to lead to antagonism and to a noteworthy MT2 subtype selectivity. Last, the new N1-C7 annulated derivatives presented herein are substantially more potent than their respective N1-C2 annulated counterparts, previously reported. (c) 2007 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2007.01.005

文献信息

• FUSED HETEROCYCLIC COMPOUND AND USE THEREOF
  申请人：SHIRAI Junya

  公开号：US20120165312A1

  公开（公告）日：2012-06-28

  The present invention relates to a serotonin 5-HT 2C receptor activator containing a compound represented by the formula wherein ring A is a 5- or 6-membered aromatic heterocycle optionally having substituent(s), and ring B is a 7- to 9-membered ring optionally having substituent(s) other than an oxo group wherein the combination of m and n (m,n) is (1,2), (2,1), (2,2), (3,1), (3,2) or (4,1), or a salt thereof or a prodrug thereof, and a fused heterocyclic compound having a serotonin 5-HT 2C receptor activating action and the like.

  本发明涉及一种含有由以下式表示的化合物的血清素5-HT2C受体激动剂： 其中环A是一种5-或6-成员芳香杂环，可选地具有取代基，环B是一种7-至9-成员环，除了一个氧代基外还可选地具有取代基，其中m和n（m，n）的组合为（1，2），（2，1），（2，2），（3，1），（3，2）或（4，1），或其盐或前药，以及具有血清素5-HT2C受体激活作用的融合杂环化合物等。
• CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF
  申请人：Matsumoto Takahiro

  公开号：US20100266504A1

  公开（公告）日：2010-10-21

  Provided are a condensed pyridine derivative having a serotonin 5-HT 2C receptor activation action, a prophylactic or therapeutic agent for a lower urinary tract symptom, obesity and/or organ prolapse and the like containing the condensed pyridine derivative, a screening method for a substance that increases leak point pressure upon a rise in the intravesical pressure or a prophylactic or therapeutic drug for stress urinary incontinence, a prophylactic or therapeutic drug for cystoceles or enteroceles, containing a substance that activates serotonin 5-HT 2C receptor, and a method of screening for a therapeutic drug for cystoceles or enteroceles, including increasing an intravesical pressure after bilateral transection of the hypogastric nerve and pudendal nerve of an animal, and measuring a closure response in the urethra, the rectum or the vagina observed at that time. A serotonin 5-HT 2c receptor activator containing a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

  提供了一种具有血清素5-HT2C受体激活作用的缩合吡啶衍生物，以及包含该缩合吡啶衍生物的预防或治疗下尿路症状、肥胖和/或器官脱垂等药物，以及增加膀胱内压力时增加泄漏点压力或预防或治疗压力性尿失禁的药物筛选方法，包含激活血清素5-HT2C受体的物质的预防或治疗膀胱脱垂或肠脱垂的药物，以及通过双侧切断动物的会阴神经和耻骨神经后增加膀胱内压力并测量尿道、直肠或阴道在此时观察到的闭合反应的膀胱脱垂或肠脱垂的治疗药物筛选方法。其中包含式的化合物的血清素5-HT2C受体激活剂：式中每个符号如规范中定义的那样，或其盐。
• PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1792629A1

  公开（公告）日：2007-06-06

  An agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that activates a serotonin 5-HT2C receptor, an agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that stimulates an androgen binding site, and a method of screening for a drug for the prophylaxis or treatment of abdominal pressure incontinence, which includes electrostimulating the abdominal muscles or a nerve controlling them of an animal to increase the abdominal pressure, and measuring the leak point pressure at that time.

  一种预防或治疗压力性尿失禁的药物，其中含有一种能激活5-羟色胺5-HT2C受体的物质；一种预防或治疗压力性尿失禁的药物，其中含有一种能刺激雄激素结合位点的物质、以及一种筛选预防或治疗腹压性尿失禁药物的方法，其中包括电刺激动物的腹部肌肉或控制腹部肌肉的神经以增加腹压，并测量当时的漏点压力。
• Preventives/remedies for stress urinary incontinence and method of screening the same
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2248524A2

  公开（公告）日：2010-11-10

  APD-356 for use as an agent for the prophylaxis or treatment of stress urinary incontinence.

  APD-356 用于预防或治疗压力性尿失禁。
• Method of screening preventives/remedies for stress urinary incontinence
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2400300A1

  公开（公告）日：2011-12-28

  The invention relates to a method of screening for a substance that increases the leak point pressure during increase in abdominal pressure and a method of screening for a drug for the prophylaxis or treatment of abdominal pressure incontinence.

  本发明涉及一种在腹压增加时增加漏点压力的物质的筛选方法，以及一种用于预防或治疗腹压失禁的药物的筛选方法。